Close Menu
Home › Castle Biosciences Uveal Melanoma Prognostic Test Garners Coverage from Multiple Payors

Castle Biosciences Uveal Melanoma Prognostic Test Garners Coverage from Multiple Payors

Jul 18, 2017
|
staff reporter

NEW YORK (GenomeWeb) – Medicare contractor Palmetto GBA has issued a final local coverage determination for Castle Biosciences' DecisionDx-UM, a prognostic test for uveal melanoma.

The LCD extends coverage for the DecisionDx-UM test to assess metastatic risk for newly diagnosed uveal melanoma patients, as well as to guide surveillance and referral to medical oncology.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Oct
03
Featured Webinar

Streamlined and High-Precision Cancer Analysis Using an Automated NGS Workflow in the Reference Lab Setting

This webinar will provide an overview of how an international reference laboratory has implemented an automated next-generation sequencing workflow with custom panels for analyzing cancer samples.

Oct
10
Featured Webinar

Laboratory Validation of a Kit-Based Liquid Biopsy NGS Assay

This webinar will provide an overview of how a pathology laboratory validated a 77-gene next-generation sequencing-based liquid biopsy assay.

Oct
24
Featured Webinar

Designing, Decoding & Delivering on Genetic Testing for Inherited Disease at Versiti

This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.

What's Popular?

In Molecular Diagnostics

  1. Scope Fluidics Subsidiary Developing 15-Minute PCR System for POC Infectious Disease MDx

    Premium

  2. Natera Finds High Performance for Noninvasive Prenatal Test in All Age Groups

    Premium

  3. Chinese Infectious Disease Dx Firm Vision Medicals Raises $14M in Series A Round

  4. Aethlon Medical Lands $1.9M SBIR Grant for Exosome Isolation Device

  5. Alzheimer's Disease Test Firm DiamiR Awarded Additional $345K From NIA

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.